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Abstract
Background: Multimodal prehabilitation is a preoperative intervention with the objective to enhance cancer
patients’ functional status which has been showed to reduce both postoperative morbidity and hospital length of
stay in digestive oncologic surgery. However, in lung cancer surgery patients further studies with higher
methodological quality are needed to clarify the benefits of prehabilitation. The main aim of the current protocol is
to evaluate the cost-effectiveness of a multimodal prehabilitation program supported by information and
communication technologies in moderate-to-high risk lung cancer patients undergoing thoracic surgery.
Methods: A Quadruple Aim approach will be adopted, assessing the prehabilitation program at the following
levels: i) Patients’ and professionals’ experience outcomes (by means of standardized questionnaires, focus groups
and structured interviews); ii) Population health-based outcomes (e.g. hospital length of stay, number and severity
of postoperative complications, peak oxygen uptake and levels of systemic inflammation); and, iii) Healthcare costs.
Discussion: This study protocol should contribute not only to increase the scientific basis on prehabilitation but
also to detect the main factors modulating service adoption.
Trial registration: NCT04052100 (August 9, 2019).
Keywords: Prehabilitation, Exercise training, Physical activity, Nutritional optimization, Smoking cessation, Cognitive
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Background
Complete surgical resection remains the best curative
option in the treatment of early stage lung cancer. How-
ever, many resectable tumors occur in patients with ab-
normal lung function, usually due to of the use of
tobacco, having chronic obstructive pulmonary disease
(COPD) and/or atherosclerotic vascular disease as
underlying comorbidities. Precisely, this group of pa-
tients has an increased risk of postoperative complica-
tions and of being considered inoperable [1, 2].
Preoperative identification of patients with increased
surgical risk [3] should be followed by strategies to pre-
vent potential postoperative complications by reducing
their incidence and/or severity, and thus minimizing
their clinical and economic impact. Therefore, the im-
plementation of effective preventive interventions is an
important milestone to achieve due to the current eco-
nomic context.
Multimodal prehabilitation is a preoperative interven-
tion with the objective to enhance cancer patients’ func-
tional status in order to improve clinical postoperative
outcomes [4]. The main interventions included in preha-
bilitation programs are exercise training, nutritional
optimization, psychological support and behavior
change, among others. In this regard, prehabilitation has
been shown to be a promising intervention to enhance
aerobic capacity consequently reducing both postopera-
tive morbidity and hospital length of stay, not only in di-
gestive cancer patients [5–7], but also in cardiovascular
surgery [8, 9]. However, in lung cancer patients under-
going thoracic surgery, further studies with larger sam-
ples and higher methodological quality are needed to
clarify the potential benefits of prehabilitation [10].
It is important to highlight, that lung cancer patients
candidates for thoracic surgery are more likely to benefit
from prehabilitation since they usually have a significant
reduction in functional capacity from multifactorial ori-
gin, namely: i) Pulmonary limitations due to COPD [11];
ii) Lean mass deficit due to the systemic effects derived
from both underlying cardiopulmonary chronic condi-
tions [12, 13] and cancer [14] and/or produced by the
sedentary lifestyle presented by these patients [15]; iii)
Functional alterations of cardiopulmonary comorbidities
[2]; iv) Side effects of the neoadjuvant therapy (radio-
therapy / chemotherapy / immunotherapy); and, v) The
state of anxiety-depression associated with the diagnosis
and surgery [16]. Therefore, the implementation of
multimodal prehabilitation programs addressing these
multifactorial etiologies in lung cancer patients undergo-
ing thoracic surgery is of paramount importance.
The main aim of the current protocol is to evaluate
the cost-effectiveness of a multimodal prehabilitation
program supported by information and communication
technologies (ICT) in moderate-to-high risk lung cancer
patients undergoing thoracic surgery. Moreover, further
secondary assessments, within a Quadruple Aim ap-
proach [17, 18], will also be performed, including: i) Pa-
tients’ experience outcomes; ii) Population health-based
outcomes; iii) Costs from the hospital perspective; and,
iv) Healthcare professional perspective outcomes. Add-
itionally, an ancillary aim of the study will be to refine
the ICT supporting the program in order to prepare
large-scale deployment of a sustainable and modular
multimodal prehabilitation services at regional (Catalo-
nia) and European level [19].
Methods / design
Study design and population
This study is a single blind randomized controlled trial.
Patients will be randomized (computer-generated ran-
dom numbers) on a 1:1 ratio, either to: i) a control
group which will follow the standard of care established
by the protocols used in our hospital; and, ii) an inter-
vention group which, besides the standard preoperative
management, will undergo a personalized multimodal
prehabilitation program at Hospital Clínic de Barcelona
(Catalonia) (Fig. 1). The sample of subjects will include
moderate-to-high risk lung cancer patients candidates to
thoracic surgery. Inclusion criteria are the following: i)
Predicted postoperative forced expiratory volume in the
first second and/or predicted postoperative lung diffu-
sion capacity for carbon monoxide < 60%, and/or; ii)
American Society of Anesthesiologists (ASA) classifica-
tion [20] 3–4; and/or, iii) age ≥ 75 years old. Exclusion
criteria are: i) Undergoing non-elective surgery; ii)
known metastatic disease before surgery; iii) unstable re-
spiratory or cardiac condition; iv) cognitive or locomo-
tive limitations precluding adherence to the program.
The study protocol and informed consent have been
evaluated and accepted by the Medical Research Ethics
Committee at Hospital Clínic de Barcelona (HCB/2018/




The preoperative standard measures consist of physical
activity recommendation and advice on both smoking
cessation and alcohol intake reduction. Moreover, in pa-
tients presenting with anemia, the anesthesiologists will
assess its etiology and treat it accordingly, and nutri-
tional intervention will be performed by a registered
dietitian in to those patients at risk of malnutrition
(Malnutrition Universal Screening Tool [21] ≥2).
Multimodal prehabilitation program
Besides the standard preoperative management afore-
mentioned, the intervention group will undergo a
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multimodal prehabilitation program. The interventions
included will be patient-centered aiming to optimize pa-
tients’ preoperative health status while enhancing their
empowerment and engagement. Most of the compo-
nents of the program will be community-based and will
be supported by a mobile solution and a technological
platform for patients’ management. The main compo-
nents of the program are described below.
(i) Supervised exercise training program: This program
will consist in ambulatory exercise training sessions
with two main components, namely: high-intensity
endurance exercise training performed on a station-
ary cycle-ergometer (Technogym® Excite Bike; Ce-
sena; Italy) and strength muscular training
(Technogym® Plurima Multistation Wall; Cesena;
Italy). Patients will undergo 3 sessions per week.
Each endurance training session will include 5 min
of warm up, 37 min of interval training, and 5 min
of cool down. The interval training will combine 3
min of high-intensity pedaling and 3 min of active
rest. Work-rate progress during the program will be
tailored on an individual basis, according to pa-
tients’ symptoms (modified Borg scale) [22], to
maximize the training effect. The strength training
session will consist in 3 series of 15 repetitions for
each of the following exercises: i) horizontal rowing;
ii) pectoral press; and, iii) quadriceps bench. Weight
progress during the program will be adapted to
patients’ tolerance with the final aim of maximizing
the training effect.
(ii) Personalized program to promote physical activity:
This will be a pedometer-based program using a
physical activity tracker linked to a mobile app.
Main physical activity-related functionalities of the
technological solution are: i) Self-monitoring of the
number of steps per day and percentage of accom-
plishment of the objective; ii) A daily motivational
message; iii) Positive reinforcement once objective
of daily steps is achieved; and, iv) Exercise and
physical activity educational material. International
recommendations for physical activity based on the
number of daily steps [23] will serve as a theoretical
framework regarding the generation of goals. All
the information monitored using the mobile solu-
tion will be registered in a technological platform
serving as a professional backend where it will be
checked and assessed by a specialized
physiotherapist.
(iii)Nutritional optimization program: Patients will
receive personalized dietary counseling from a
registered dietician. Based on the initial evaluation,
patients will receive recommendations of a healthy
balanced diet or a diet adapted to their digestive
symptoms, if present. The daily amount of protein
intake capable of producing a positive nitrogen
balance in these patients is estimated to be close to
2 g·Kg− 1·day− 1. This protein intake (1.5–2 g·Kg−
Fig. 1 Study flow-chart
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1·day− 1) will be ensured in patients with adequate
kidney function, distributed in three main daily
meals, by means of food enrichment, and/or
nutritional supplementation such as whey protein
powder or casein. Sufficient caloric supply will be
ensured as a mean to guarantee proper protein
utilization. Moreover, alcohol intake abstinence will
be highly recommended and professional help
offered if required. Moreover, personalized
educational material as well as follow-up surveys
will also be provided using the mobile app. As well
as in the physical activity promotion program, the
nutritional information will be registered in the
technological platform and assessed by the dietician.
(iv)Smoking cessation program: The treatment will
consist in the use of both cognitive behavioral
intervention and pharmacological therapy either by
varenicline and/or nicotine replacement therapies.
A weekly monitoring will be performed to evaluate
the evolution of their abstinence symptoms and
craving control.
(v) Cognitive behavioral therapy: The intervention will
consist on weekly group sessions conducted by a
clinical health psychologist, including
psychoeducation, motivational and behavioral
change, self-efficacy and adherence enhancement,
coping strategies acquisition and patient empower-
ment. The main objectives of the cognitive behav-
ioral therapy will be to reinforce patients’
motivation, to provide coping strategies to manage
stress and to foster patients’ engagement for healthy
lifestyles (i.e. physical activity, nutritional habits and
smoking cessation) according to the program objec-
tives. Group sessions will be complemented by pro-
viding educational material, audio guides for coping
strategies exercises and motivational text messages
using the mobile solution. Patients with comorbid
psychopathology will be addressed to a specialized
service.
Study variables
As stated in the introduction of the present manuscript,
study outcome variables will follow a Quadruple Aim
approach [17, 18]. Firstly, from the patients’ experience
perspective, main outcome variables included will be per-
son centeredness by the Person Centered Coordinated
Experience Questionnaire [24] and continuity of care by
the Nijmegen Continuity Questionnaire [25]. Moreover,
focus groups and structured interviews will be also
undertaken to identify facilitators and barriers to preha-
bilitation. Secondly, population health-related outcome
variables will be hospital and intensive-care length of
stay, number and severity of postoperative complications
[26], number of hospital readmissions and emergency
visits at 30 days, physical activity using Yale Physical Ac-
tivity Survey (YPAS) [27], aerobic capacity measured by
a standard cardiopulmonary exercise test, self-perceived
health status using the Short-Form (36) health survey
(SF-36) [28], anxiety and depression levels using the
Hospital Anxiety and Depression score (HAD) [29], lean
mass index measured by bioimpedanciometry, and levels
of systemic inflammation [30] by determinations of C-
reactive protein (CRP), ultrasensitive CRP, TNF-α Fac-
tor, γ-interferon and interleukins 6 and 10. Thirdly, hos-
pital costs will be assessed, including: i) Patient-
chargeable costs (i.e. pharmacy and blood bank); ii)
Tariff-chargeable costs (i.e. medical care, diagnostic
techniques, laboratories, specialist consultations, hospital
length of stay and hostelry); and, iii) Other costs (i.e.
support and structural costs). Last, but not least, health-
care professionals’ perspective will be assessed by Advan-
cing Care coordination and Telehealth deployment at
Scale (ACT@Scale) questionnaire [31]. Professionals’
perspectives (i.e. healthcare professionals, policy makers,
healthcare companies’ representatives and health tech-
nology agents) will be also assessed by means of focus
groups and structured interviews.
Descriptive variables will include socio-demographic,
environmental, and interpersonal data, smoking status,
alcohol intake, comorbidities, pulmonary function tests
[32–34] and arterial blood gases. All data will be col-
lected in a technological platform.
Sample size calculation and statistical analysis
Sample was calculated with GRANMO program [35]
taking hospital length of stay reduction as the main out-
come measure. Accepting an α-risk of 0.05 and a β-
risk< 0.2 in a bilateral contrast and assuming a 15% of
follow-up losses and a standard deviation of 3.1, 79 pa-
tients in each group will identify a statistically significant
reduction ≥1.5 days of length of hospital stay.
Data will be analyzed to explore and assess the effect
of the intervention on the use of health resources and
clinical impact by comparing the intervention group
with the control group using hypothesis tests. The char-
acteristics of the intervention group and the control
group will be compared using Student’s t-test, Kruskal-
Wallis or Chi2, according to the distribution of the vari-
ables. The effect of the intervention will be studied by
intention to treat through regression analysis (linear, lo-
gistic, Cox or Poisson, depending on the distribution of
the variable), including the exposure to the intervention
as the main variable and as co-variables those in which
the intervention group and the control group are differ-
ent at baseline, if there were any present. A cost-
effectiveness study will be carried out from the perspec-
tive of the hospital, taking into account the costs of the
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intervention and the expenses related to the disease dur-
ing the follow-up (30 days).
Discussion
The current manuscript reports a study protocol to as-
sess the impact of multimodal prehabilitation in
moderate-to-high risk patients undergoing lung cancer
resection within a Quadruple Aim approach [17]. In this
regard, the comprehensive evaluation strategy presented
will provide novel information on prehabilitation at dif-
ferent levels, contributing to increase the scientific basis
on the field, and also potentially detecting the main fac-
tors that modulated service adoption in the clinical
practice.
It is well-known that novel healthcare services within
an integrated care approach, such as prehabilitation in
cancer surgery, are applied in complex patients and set-
tings entailing the connectivity, alignment, and collabor-
ation of several stakeholders and healthcare tiers.
Therefore, this protocol also envisages the assessment of
the practicalities for service accessibility, sustainability
and scalability by means of focus groups and structured
interviews with patients, caregivers and professionals.
The community setting has to be acknowledged as a
cornerstone for the adoption and scalability of prehabili-
tation programs. The link between the hospital and the
community setting should be possible thanks to ICT act-
ing as enabling tools at three levels: monitoring, commu-
nication and patient management. In this protocol we
postulate a mobile phone solution and a technological
platform to optimize patients’ adherence to the work
plan.
Finally, besides traditional prehabilitation outcomes
(i.e. hospital length of stay, postoperative complications,
cost-effectiveness), the protocol reported in this article
will also explore novel aspects in the field, such as the
role of systemic inflammation as a potential biomarker
of prehabilitation response [30].
The approach of this study protocol should contribute
to generate recommendations for transferability and re-
finement of prehabilitation and perioperative cancer
care.
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